Metastatic Solid Tumor
Conditions
Brief summary
This is a two-part, open-label phase 1 study to evaluate safety and preliminary efficacy of M-CENK Suspension for Infusion, Cryopreserved, and N-803 for subcutaneous administration in subjects with locally advanced or metastatic solid tumors. The study consists of two cohorts: cohort 1 includes subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment; and cohort 2 that includes subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies. The two cohorts will be conducted simultaneously.
Detailed description
Both cohorts will be enrolled simultaneously. Both cohorts have a part A (apheresis) and cohort 2 has a part B (M-CENK treatment \[one bag has a 100 mL cell suspension containing 0.25 to 0.75 x 109 cells\] and N-803 treatment). Up to 40 subjects may be enrolled in cohort 1. Subjects in cohort 1 will participate in apheresis collection of MNCs prior to receiving disease specific first-line therapy per primary oncologists' recommendations. Subjects who have completed apheresis in cohort 1 may subsequently enroll in cohort 2 part B if they have progressive disease after ≥ 2 prior therapies or if they have progressive disease within 12 months of receiving neoadjuvant or adjuvant chemotherapy. They must also meet the inclusion criteria to participate in the treatment phase (cohort 2 part B). Additionally, all subjects will be re-evaluated to confirm that they still meet the specified eligibility criteria once the M-CENK cells are manufactured and prior to the first administration of M-CENK. The Sponsor will approve the subject's continued eligibility prior to receiving the manufactured M-CENK cells. Up to 21 subjects may be enrolled in cohort 2 part A so that up to 11 subjects receive at least 1 dose of M-CENK. A dose is a single administration of M-CENK cells or a single administration of N-803. Subjects in cohort 2 part A will undergo an apheresis collection of MNCs prior to receiving approximately 4 weeks of disease-specific therapy per oncologists' recommendations while the M-CENK cells are being manufactured for use in the treatment phase (cohort 2 part B). Subjects will be evaluated for eligibility in inclusion/exclusion criteria prior to enrollment into part B. Additionally, all subjects will be re-evaluated to confirm that they still meet the specified eligibility criteria once the M-CENK cells are manufactured and prior to the first administration of M-CENK. The Sponsor will approve the subject's continued eligibility prior to receiving the manufactured M-CENK cells. M-CENK cells, manufactured from the autologous apheresis product, may be administered up to 10 times weekly starting on study day 1 with a minimum of 7 days between each M-CENK dose depending on the availability of cells and that there is no contra-indication to administer cells. Subjects will receive up to 5 doses of N-803 SC every 2 weeks prior to every other dose of M-CENK (ie, odd number M-CENK doses).The treatment may be administered for up to 10 doses of M-CENK, if the subject tolerates treatment, the doses of M-CENK cells are available, and the Investigator believes there may be potential benefit to the subject. Safety endpoints include assessments of TEAEs, SAEs, and clinically significant changes in safety laboratory tests, and vital signs. Toxicities will be graded using CTCAE Version 5.0, or in the case of CRS, using a specified grading system. Safety will be monitored throughout the study. The treatment of the initial 3 subjects in cohort 2 part B will be staggered with at least a 2-week interval between each subject. After the first 3 subjects in cohort 2 part B are treated, the treatment of existing subjects in cohort 2 part B will be paused after the 14-day toxicity assessment period for a safety evaluation by the Safety Review Committee (SRC). Based on the SRC safety evaluation, the treatment of the subsequent subjects can proceed if the safety evaluation from the initial 3 subjects in part B suggests that the therapy is safe. There will be another safety review after all subjects in cohort 2 have completed the 14-day toxicity assessment period.
Interventions
BIOLOGICALN-803 (Cohort 2 part B)
N-803 15 μg/kg will be administered subcutaneously prior to every other dose of M-CENK for up to 5 doses of N-803.
BIOLOGICALM-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)
M-CENK will be administered up to 10 times weekly via intravenous (IV) infusion starting on study day 1 with a minimum of 7 days between each M-CENK dose. The dose of MCENK will be 0.25 - 0.75 × 10e9 cells per infusion.
OTHERApheresis collection of MNCs (part A)
Subjects in cohort 1A will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study.
Sponsors
ImmunityBio, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
Cohorts 1 and 2, Part A: * Age ≥ 18 years old. * Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines. * Have histologically confirmed locally advanced, unresectable, or metastatic solid tumor. * For subjects with genetic mutations or alterations in solid tumors (e.g. NSCLC, pancreatic cancer, melanoma), the subjects must have received prior appropriate disease specific targeted therapy and have progressed. * Have at least 1 measurable lesion and/or non-measurable disease evaluable in accordance with RECIST Version 1.1. * For subjects with a history of human immunodeficiency virus (HIV) * Subjects with CD4+ T-cell (CD4+) counts ≥ 350 cells/uL and without a history of AIDS defining opportunistic infections. * For subjects with a history of hepatitis B virus (HBV) * Subjects who are chronic carriers of HBV infection (HBsAg-positive, undetectable or low HBV DNA, and normal ALT) who are not on HBV therapy, or in individuals who have serologic evidence of a resolved prior HBV infection (i.e., HBsAg-negative and anti-HBc-positive), anti-HBV prophylaxis should be assessed prior to enrollment. * Subjects with chronic HBV infection with active disease who meet the criteria for anti HBV therapy should be on a suppressive antiviral therapy prior to enrollment. * For subjects with a history of hepatitis C virus (HCV) * Subjects with a history of HCV infection should have completed curative antiviral treatment and have a HCV viral load below the limit of quantification are eligible. * Subjects who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible. * Subjects on concurrent HCV treatment and have HCV below the limit of quantification are eligible. Note: Subjects who have a history of HIV/HBV/HCV or are seropositive will require Infectious Disease Marker (IDM) testing prior to apheresis collection. * Subjects who currently have non-progressive brain metastasis and were previously treated with surgical resection/debulking, radiation, and stereotactic radiosurgery. * Able to undergo an Apheresis procedure: * Have adequate venous access * Able to sit or recline for 5-6 hours with limited movement * Hemoglobin must be ≥ 9.0 g/dL * Platelet count must be ≥ 100,000 cells/mm3 * Vital signs must be within normal range * Negative serum pregnancy test for females of childbearing potential. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Ability to attend required study visits and return for adequate follow-up, as required by this protocol. * Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 30 days after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 30 days after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), 2 forms of barrier methods (eg, condom, diaphragm) used with spermicide, and intrauterine devices (IUDs). Cohort 2, Part B subjects only: * Have documented progressive disease after receiving treatment with at least 2 prior lines of therapy or not be a candidate for therapy of proven efficacy for their disease. Prior immune therapy and prior treatment with a checkpoint inhibitor as per FDA indication for current standard of care therapy is allowed. * Subjects cannot receive M-CENK before a 14-day washout period following treatment with an approved chemotherapy and approved or investigational immunotherapy (eg PD-1/PD-L1 inhibitors, CAR NK cells \[PD-L1 t-haNK\], N-803). A repeat lab at least 14 days after completion of the washout period is required. * Subjects cannot receive M-CENK before a 30-day washout period following treatment with investigational chemotherapy. A repeat lab at least 30 days after completion of the washout period is required. * Ability to attend required study visits and return for adequate follow-up, as required by this protocol. * Agreement to practice effective contraception for female subjects of child-bearing potential and nonsterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 30 days after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 30 days after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), 2 forms of barrier methods (eg, condom, diaphragm) used with spermicide, and intrauterine devices (IUDs).
Exclusion criteria
(Cohorts 1 and 2, Part A): There is no
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis. | Study Day 1, assessed for up to 1 week | \- Safety of apheresis collection as indicated by incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, or in the case of cytokine release syndrome (CRS), using the specified grading system. |
| Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with abnormal vital signs | From M-CENK Dose Number 1, assessed for up to 1 day | \- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation |
| Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with clinically significant laboratory tests | From M-CENK Dose Number 1, assessed for up to 1 day | \- Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) performed within 1 calendar day prior to first dose. |
| Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of TEAEs and SAEs after the first dose of M-CENK and the first dose of N-803 (M-CENK Dose Number 1) | From M-CENK Dose Number 1 up to 30 days, assessed for up to 30 days | \- Incidence of TEAEs and SAEs, graded using the NCI CTCAE Version 5.0, or in the case of CRS using the specified grading system. |
| Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by number of participants with abnormal vital signs. | From Baseline/Screening through Study Day 1, assessed for up to 28 days | \- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation |
| Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of participants with clinically significant laboratory tests. | From Baseline/Screening through Study Day 1, assessed for up to 1 day | \- Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) performed within 1 calendar day prior to apheresis collection. Hematology test will be performed pre- and post- apheresis collection. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Objective (cohort 2, part B): Evaluate the overall safety profile of up to 10 doses of M-CENK and up to 5 doses of N-803 for SC administration in subjects with relapsed or refractory (R/R) solid tumors by the number of TEAEs and SAEs. | From M-CENK Dose Number 1 through End of Study (up to 12 months from first dose), assessed for up to 12 months | \- Incidence of TEAEs and SAEs, graded using the NCI CTCAE Version 5.0, or in the case of CRS using a specified grading system. |
| Secondary Objective (cohort 1 and cohort 2, part A subjects): Evaluate the quantity and quality of the manufactured investigational cells from subjects in cohort 1 vs. cohort 2 by the number of MNCs for manufacturing M-CENK cells. | Study Day 1 | \- Number of MNCs for manufacturing M-CENK cells |
| Cohort 1 and cohort 2, part A subjects: Evaluate the quantity and quality of the manufactured cells from subjects in cohort 1 vs. cohort 2 by the number of MNCs collected and the % of natural killer (NK) cells. | Study Day 1 | Number of MNCs collected and the percentage of natural killer (NK) cells (CD56/CD16 positive) after a 2 blood volume apheresis collection. |
| Cohort 1 and cohort 2, part A subjects: Evaluate the quantity and quality of the manufactured cells from subjects in cohort 1 vs. cohort 2 by the number, phenotype (CD56/CD16 positive and CD3 positive cells), and function of M-CENK cells. | Study Day 1 | \- Number, phenotype (CD56/CD16 positive and CD3 positive cells), and function of M-CENK cells as measured by flow cytometry and interferon (IFN) γ production, and cytotoxicity following enrichment and expansion of the NK cells ex vivo. |
| Secondary Objective (cohort 1 and cohort 2, part A subjects): Evaluate the quantity and quality of the manufactured investigational cells from subjects in cohort 1 vs. cohort 2 by the number of cryopreserved aliquots of manufactured M-CENK cells. | Study Day 1 | \- Number of cryopreserved aliquots of manufactured M-CENK cells. |
| Cohort 2, part B subjects: Evaluate overall safety profile of up to 10 doses of M-CENK and up to 5 doses of N-803 in subjects with relapsed or refractory (R/R) solid tumors by the number of participants with clinically significant laboratory tests. | From M-CENK Dose Number 1 through End of Study (up to 12 months from first dose), assessed for up to 12 months | * Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) and will be performed within 1 calendar day prior to dosing. * Vital signs. |
| Cohort 2, part B: Evaluate the overall safety profile of up to 10 doses of M-CENK and up to 5 doses of N-803 for SC administration in subjects with relapsed or refractory (R/R) solid tumors by the number of of participants with abnormal vital si | From M-CENK Dose Number 1 through End of Study (up to 12 months from first dose), assessed for up to 12 months | \- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation |
| Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the objective response rate (ORR) by the percentage of subjects that achieve a confirmed complete or partial overall response | From Baseline/Screening through End of Study (up to 12 months from first dose), measured at 4 weeks, every 8 weeks, EOT, EOS | \- ORR will be measured 4 weeks after the first dose of M-CENK then every 8 weeks (± 1 week), and at EOT and EOS, in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and modified RECIST guidelines for immunotherapy trials (iRECIST) and the percentage of subjects that achieve a confirmed complete or partial overall response will be presented. The 95% confidence interval of the response rate will be presented. Response will be assessed using both RECIST and iRECIST. |
| Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the progression-free survival (PFS) by the | From M-CENK Dose Number 1 to the date of disease progression or death (any cause), assessed for up to 12 months | \- PFS will be measured 4 weeks after the first dose of M-CENK then every 8 weeks (± 1 week), and at EOT and EOS by RECIST Version 1.1 and iRECIST and will be evaluated using Kaplan-Meier methods. PFS will be defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. |
| Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the overall survival (OS) from the first date of treatment to the date of death. | From M-CENK Dose Number 1 to the date of death (any cause), assessed for up to 12 months | Overall Survival will be evaluated using Kaplan-Meier methods. OS will be defined as the time from the date of first treatment to the date of death (any cause). Subjects who are alive at the end of follow-up will be censored at the last known date alive. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory Objective (cohort 1 and cohort 2, part A subjects): Evaluate and compare immune profiles of whole blood and apheresis product by frequency, number, phenotype, and proliferation of NK cells as measured by flow and mass cytometry. | From Baseline/Screening through Study Day 1 | \- Frequency, number, phenotype, and proliferation of NK cells as measured by flow and mass cytometry. Function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity. \- Serum cytokines. |
| Exploratory Objective (cohort 2, part B subjects): Evaluate whole blood immune profiles by measuring serum cytokines. | From Baseline/Screening through End of Study, assessed for up to 12 months | \- Serum cytokines. |
| Exploratory Objective (cohort 1 and cohort 2, part A subjects): Evaluate and compare immune profiles of whole blood and apheresis product by frequency and phenotype of immune cells as measured by flow and mass cytometry.. | From Baseline/Screening through Study Day 1 | \- Frequency and phenotype of immune cells as measured by flow and mass cytometry. |
| Exploratory Objective (cohort 2, part B subjects): Evaluate whole blood immune profiles by function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity. | From Baseline/Screening through End of Study, assessed for up to 12 months | \- Function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity. |
| Exploratory Objective (cohort 2, part B subjects): Evaluate whole blood immune profiles by frequency and phenotype of immune cells as measured by flow and mass cytometry. | From Baseline/Screening through End of Study, assessed for up to 12 months | \- Frequency and phenotype of immune cells as measured by flow and mass cytometry. |
| Exploratory Objective (cohort 1 and cohort 2, part A subjects): Evaluate and compare immune profiles of whole blood and apheresis product by measuring serum cytokines. | From Baseline/Screening through Study Day 1 | \- Serum cytokines. |
| Cohort 1/2, part A subjects: Evaluate and compare immune profiles of whole blood and apheresis product by function of NK cells and NK cell receptor profile by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity. | From Baseline/Screening through Study Day 1 | Exploratory Objective: * Function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity. * Serum cytokines. |
Countries
United States
Outcome results
None listed